SR 12813

Drug Profile

SR 12813

Latest Information Update: 21 Jan 2008

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; ILEX Research-Europe
  • Class Antihyperlipidaemics; Bisphosphonates
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 07 Mar 2001 Symphar has been acquired by ILEX Oncology and is now called ILEX Research-Europe
  • 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 17 Oct 1997 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top